OVERVIEW
is a Clinical stage biopharmaceutical company focused on on immuno-modulatory antibodies for cancer treatment.
Pipeline includes several monoclonal antibodies targeting tumorigenic proteins (CA-125, MUC-1, PSA, and Her2/neu) with the potential for development in multiple indications.
3 monoclonal xenotypic IgG1 antibodies including lead oregovomab, in addition to anti-MUC1, and anti-PSA antibodies 3 monoclonal antibodies fully human chimeric IgE (binding MUC1, PSA, and HER2/neu)
is an innovative immuno-oncology company
dedicated to developing synergistic combinations which incorporate our novel, proprietary portfolio of antibodies which have been engineered to stimulate the proliferation of antigen-specific T-cells with chemotherapeutics and other immunomodulatory agents to improve clinical outcomes in a broad range of cancers.
The highly specific antibodies to a range of antigens which have been demonstrated has been developed to be implicated in tumorigenesis. Dendritic cell uptake of the antigen via Fc results in unique antigen presentation and cross presentation and generates a robust immune response resulting in antigen-specific cytotoxic and helper T-cell expansion. We have studied our antibodies in combination with a broad range of chemotherapeutic and other immunomodulatory agents in both preclinical and clinical studies.
The field of immuno-oncology (or cancer immunotherapy) has made significant progress in the past decade. Cancer immunotherapies generally work by interfering with the inhibitory signals produced by tumors against specific constituents of the immune system. Because such inhibitory signals are mediated by "immune checkpoint" cell-surface molecules, the first generation of cancer immunotherapies are generally known as checkpoint inhibitors. The notable clinical efficacy of some checkpoint inhibitors appears to be associated with the activity of effector lymphocytes, mainly tumor-infiltrating Teffector cells. However, there continues to be a significant unmet need. While checkpoint inhibitors have produced significant benefit for some patients, a large segment of patients fail to benefit from these therapies.
As we learn more about the various and redundant tumor-triggered immunosuppressive pathways, there is an evolving view that in order for these targeted drugs to be broadly effective, we will need to develop combinations that at once, interfere with a number of these mechanisms while triggering a more robust immune stimulatory response.
-
-
- US and Global Phase 3 Protocol (Initiation)
- NCT number : 04498117
- Orphan Drug & Fast Track Designation in USA
-
-
- Phase 2 Promising results
- Study arm median PFS 41.8M
- Control arm median PFS 12.2M
-
-
- Engaged global CRO IQVIA, GOG Foundation
- Frontline Ovarian Cancer Drug Phase 3
- Alternate neoadjuvant regimen Ovarian cancer Phase1/2
- Recurrent Ovarian Cancer Phase 1/2 Other Pipeline Candidates:
- Pancreatic Cancer Drug Phase 1/2 – MAb AR20.5
- Breast Cancer Pre-Clinical – Anti Her2/neu IgE
-
-
- Patent protection until 2037
- Regulatory exclusivity where patent is not issued
-
-
Jonathan S. Berek,
MD, MMS -
- Brown University and Johns Hopkins School of Medicine
- Professor of Laurie Kraus Lacob in Stanford Medical School
- Professor, at the Stanford University School of Medicine.
- Director, Stanford Women's Cancer Center. Senior Advisor, Stanford Cancer Institute.
- Director, Stanford Health Communication Initiative
- American Cancer Society Honoree 2019 Women's Oncology Committee, FIGO (2016-Current)
-
-
-
Michael Tony
Hollingsworth -
- B.A. in Biology, cum laude at Wake Forest University (WFU)
- Ph.D. in Microbiology & Immunology at the WFU Graduate School of Arts and Sciences.
- Professor of the Cancer Institute at Nebraska University Medical Center (Eppley Institute)
- National Cancer Institute (UNMC Fred & Pamela Buffet Cancer Center Fred & Pamela Buffett Cancer Center) Associate Director of Basic Research (2016- Current)
-
-
-
Madi Madiyalakan
Ph.D, -
- MS (chemistry) and Ph.D. (biochemistry) from Madras University
- Cornell University, Roswell Park Cancer Institute, Research Associate /Research Affiliate
- Centre national de la reserve (CNRS, France) Tenured Faculty Member
- CEO of Oncoquest Inc
- CEO of QuestPharmaTech
-
-
-
J. Mark
Lievonen -
- MBA in Finance & Marketing, Schulich School of Business,York University
- Chartered Professional Accountant, FCPA, FCA
- (Former) President of Sanofi Pasteur Limited
- (Former) Director of Quest PharmaTech
-